ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)
Anticancers
- Erlotinib Hydrochloride
- Sorafenib Tosilate
- Dasatinib Hydrate
Circulatory System Drugs
- Rivaroxaban
REFERENCE STANDARDS
1056FNL
Vilanterol Trifenatate
CAS No. 503070-58-4
C44H49Cl2NO7
MW 774.77
IM207
Vilanterol Trifenatate Impurity 1
C26H35Cl2NO5
MW 512.47
IM233
Vilanterol Trifenatate Impurity 2
C27H37ClBrNO5
MW 570.94
IM229
Vilanterol Trifenatate Impurity 3
C38H60N2O8
MW 672.89
IM107
Vilanterol Trifenatate Impurity 4
C27H33Cl2NO6
MW 538.46
IM407
Vilanterol Trifenatate Impurity 5
C23H31Cl2NO5
MW 472.40
IM133
Vilanterol Trifenatate Impurity 6
C28H35BrClNO6
MW 596.94
IM433
Vilanterol Trifenatate Impurity 7
C24H33BrClNO5
MW 530.88
IM428
Vilanterol Trifenatate 8
C15H23Cl2NO2
MW 320.25
IM422
Vilanterol Trifenatate Impurity 9
C48H64Cl4N2O9
MW 954.84
KSB2001
Sorafenib Tosylate
CAS No. 475207-59-1
C28H24ClF3N4O6S
MW 637.03
KSB2002
Dasatinib
CAS No. 302962-49-8
C22H26ClN7O2S
MW 488.01
KSB2020
Dexmedetomidine hydrochloride
CAS No. 145108-58-3
C13H16N2· HCl
MW 236.74
INTERMEDIATE
| Product | CAS # | Specification | Category |
| Cyclo(Arg-Gly-Asp-D-Phe-Lys), c(RGDfK) | 161552-03-0 | HPLC purity > 97% | An RGD tumor-targeting peptide |
| c(RGDfK)-PEG4-NH2 | N/A | HPLC purity > 95% | RGD tumor targeting peptide with PEG spacers |